Spero Therapeutics, a multi-asset clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, is dedicated to identifying and developing innovative treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. The company recently announced that they will share their first quarter 2024 financial results and provide a business and pipeline update on May 15, after the market closes. They have decided not to host a conference call for this announcement but plan to resume quarterly earnings calls when the second quarter 2024 results are released.
Spero Therapeutics is at the forefront of developing novel treatments for rare diseases and MDR bacterial infections. Their lead product candidate, SPR720, is an oral first-line treatment for nontuberculous mycobacterial pulmonary disease (NTM-PD) and is currently being studied in a Phase 2A proof of concept trial. NTM-PD is a rare lung disease caused by non-tuberculous mycobacterial infections.
Another innovation from Spero Therapeutics is SPR206, an investigational IV-administered direct-acting next-generation polymyxin that demonstrates antibiotic activity against MDR Gram-negative pathogens such as carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. The FDA has cleared an Investigational New Drug (IND) application to advance SPR206 into a Phase 2 clinical trial for participants with hospital-acquired or ventilator-associated bacterial pneumonia.
In addition to these two candidates, Spero Therapeutics is also developing Tebipenem HBr, an oral drug that is in a Phase 3 registrational trial for the treatment of complicated urinary tract infections including pyelonephritis. GSK has been granted an exclusive license to commercialize tebipenem HBr in most territories except certain Asian territories.
